Atorvastatine EG

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Atorvastatine EG

Quick Facts

Property Description
Active ingredient Atorvastatin (as calcium salt)
Form Film-coated tablets
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Management of high blood lipids (dyslipidemia)
Origin Synthetic

What Type of Medicine is Atorvastatine EG?

Atorvastatine EG is a recognized prescription-only medication whose active agent, Atorvastatin, belongs to the pharmacological class of HMG-CoA Reductase Inhibitors. These agents are commonly known as statins, a group of synthetic compounds central to lipid therapy. The drug is clinically recognized for its high efficacy, often being categorized as a high-intensity statin due to its potent effect on blood lipid levels. Atorvastatine EG is a brand containing the established INN, ensuring its identity and efficacy align with standards for managing dyslipidemia.

Composition and Pharmaceutical Form

The medicine is defined as a single-component product whose sole active ingredient is Atorvastatin, typically compounded as the calcium salt. This synthetic substance is prepared as a film-coated tablet designed for oral administration. This particular pharmaceutical form provides a standardized and precise delivery system. The coating and excipients ensure the tablet maintains its stability and allows for controlled systemic absorption of the active compound to exert its effect, a formulation strategy crucial for modern lipid-regulating agents.

General Purpose of Atorvastatin

The general purpose of the Atorvastatin component is the proactive management of elevated fatty substances in the blood, such as cholesterol. The substance works by selectively inhibiting the HMG-CoA reductase enzyme, a necessary step in the body's natural cholesterol biosynthesis within the liver. This action leads to a significant increase in the clearance of low-density lipoprotein cholesterol (LDL-C), often referred to as "bad cholesterol," from the circulation. Controlling these lipid levels is the fundamental benefit of the drug, supporting overall cardiovascular health management.

Advertisements

What side effects are possible with Atorvastatine EG?

Possible side effects and safety information

Atorvastatine EG's safety profile is defined by officially documented adverse reactions classified by frequency and the body system affected, consistent with regulatory guidelines (e.g., EMA/FDA). The primary safety focus centers on the Musculoskeletal system and Hepatobiliary disorders.

Frequency Classification Examples of Officially Documented Adverse Reactions
Common (ge 1/100 to < 1/10) Nasopharyngitis, Hyperglycaemia, Headache, Myalgia (muscle pain), Arthralgia (joint pain), Diarrhea, Abnormal liver function test results.
Uncommon (ge 1/1,000 to < 1/100) Insomnia, Amnesia, Hepatitis, Urticaria (hives), Weight gain.
Rare (ge 1/10,000 to < 1/1,000) Myopathy, Rhabdomyolysis, Angioedema.
Very Rare (< 1/10,000) Hepatic failure, Anaphylaxis, Stevens-Johnson syndrome.

Serious adverse reactions officially documented include Rhabdomyolysis (severe muscle breakdown), Myopathy, and Hepatic Failure. The risk of myopathy is officially considered higher in the elderly (age >65) and patients with renal impairment.

Regulatory labeling notes that significant liver enzyme elevations are often dose-related and reversible upon adjustment.

The medicine is formally contraindicated by regulatory bodies in the presence of active liver disease or unexplained persistent hepatic transaminase elevations, and during pregnancy and lactation.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Atorvastatine EG overdosage states there is no specific treatment known. Management is strictly symptomatic and involves supportive measures instituted as required. Due to the extensive plasma protein binding of the active substance, regulatory sources indicate that haemodialysis is not expected to significantly enhance clearance.

Overdose manifestations are defined by the serious adverse effects associated with high exposure. These include signs of Myopathy, such as unexplained muscle pain, tenderness, or weakness, potentially accompanied by fever or malaise. Severe outcomes documented in regulatory sources include Rhabdomyolysis, a potentially life-threatening condition that can lead to acute kidney injury or renal failure. Signs of serious hepatic injury, such as jaundice or elevated serum transaminases, are also identified. Risk factors for severe muscle effects are noted to be increased in populations with advanced age and renal impairment.

When to Seek Immediate Medical Help

Immediate medical attention is required for severe systemic reactions, including swelling of the face, tongue, or throat, or difficulty breathing. Patients must also promptly report any unexplained muscle symptoms to a healthcare professional, as this is a key trigger for intervention. Required monitoring following possible high exposure includes the measurement of Creatine Kinase (CK) levels and Liver Function Tests.

Advertisements

Therapeutic Uses of Atorvastatine EG

What Atorvastatine EG Treats: Main Uses and Benefits

Atorvastatine EG is primarily used to manage symptoms related to systemic imbalance, specifically addressing abnormally high concentrations of fatty substances in the blood. The medication is commonly used to help patients cope with the chronic condition of dyslipidemia, which involves reducing elevated levels of Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides.

The primary therapeutic purpose is to play a role in managing the risk of severe cardiovascular events. It is generally relevant for conditions including primary hypercholesterolemia, mixed dyslipidemia, coronary artery disease, and Familial Hypercholesterolemia in adolescents and adults.

“The medication is commonly used to help with the symptomatic management of the chronic condition, assisting with the goals of long-term risk management.”


Quick Fact: Relief for Asymptomatic Cardiovascular Risk
Primary Focus Chronic lipid abnormalities (high LDL-C, triglycerides) that are factors in cardiovascular risk.
Main Benefit Supports the patient during the management of risk factors associated with a major event, such as a heart attack or stroke.
Typical Contexts Applied in the context of chronic supportive management for high-risk patients and those with inherited (Familial) high cholesterol.

n---

The use in high-risk groups, such as those with Type 2 Diabetes Mellitus, is relevant for easing the overall burden of cardiovascular risk.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults for all approved uses. Pediatric patients aged 10 years and older for specific genetic cholesterol conditions, namely Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolaemia (HoFH).
Populations for whom use is contraindicated Patients with active liver disease or unexplained persistent elevations of serum transaminases (liver enzymes) greater than three times the upper limit of normal (3 imes ULN). Patients with known hypersensitivity to the active substance (atorvastatin) or any component of the medication.
Age-related eligibility rules Minimum age is 10 years for use in children with specific familial hypercholesterolemia. Use in children younger than 10 years is generally not established or recommended.
Condition-specific eligibility rules Pregnancy and Breastfeeding are contraindicated. Women of childbearing potential are required to use appropriate contraceptive measures. Caution is advised for patients with predisposing factors for muscle disorders (myopathy/rhabdomyolysis), including uncontrolled hypothyroidism, renal impairment, or advanced age (over 70).

Eligibility Classifications

Category Regulatory Status
Eligibility severity classification Absolute Contraindication: Active liver disease, pregnancy, and breastfeeding. Conditional Use/Caution: Predisposing factors for myopathy, history of liver disease, and substantial alcohol consumption.
Eligibility-context constraints Usage is prohibited in certain physiological states (pregnancy/lactation) and in the presence of active organ pathology (active liver disease).

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by establishing mandatory exclusions (absolute contraindications) based on liver health and reproductive status. For populations where use is allowed (adults and children 10+ for specific conditions), the profile imposes explicit requirements for caution and pre-treatment assessment when major risk factors for muscular injury are present.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Atorvastatine EG are officially documented based on how co-administered substances affect the drug's plasma concentration or increase the risk of specific adverse effects, particularly muscle toxicity. This information is derived from government regulatory sources.

Pharmacokinetic Interactions and Restrictions

Atorvastatin's concentrations can be significantly increased when co-administered with drugs that inhibit the CYP3A4 enzyme or the OATP1B1 transporter. These inhibitors include potent agents such as Cyclosporine, the antifungals Itraconazole, the antibiotic Clarithromycin, and certain HIV/HCV Protease Inhibitors.

Conversely, co-administration with inducers like Rifampin may lead to reduced atorvastatin concentrations. For Rifampin, the official documentation requires simultaneous administration to maintain appropriate exposure.

Officially Documented Prohibitions and Risks

Classification Interacting Substance/Condition
Contraindicated Combination Glecaprevir plus Pibrentasvir (HCV antivirals)
Additive Risk (Myopathy) Fibric Acid Derivatives (e.g., Gemfibrozil) and Lipid-Modifying Doses of Niacin (≥ 1 g/day)

Consumption of large quantities of grapefruit juice (exceeding 1.2 liters daily) is officially not recommended, as it can increase plasma levels. Furthermore, regulatory labeling documents that the presence of Hepatic Impairment results in markedly increased atorvastatin plasma concentrations.

Advertisements

Mechanism of Action

How Atorvastatine EG Works

The mechanism of action for Atorvastatin is a two-step cascade localized primarily within the liver, resulting in the sustained reduction of circulating atherogenic lipoproteins.


Inhibition of Cholesterol Biosynthesis

Atorvastatin functions as a selective, competitive inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme regulates the rate-limiting step in the mevalonate pathway, which is the primary source of cholesterol production in the liver cell. By blocking this enzymatic step, the drug reduces internal cholesterol synthesis.


Increased Clearance of LDL Particles

The resulting shortage of internal cholesterol triggers a critical cellular feedback mechanism: the upregulation (increased density) of Low-Density Lipoprotein (LDL) receptors on the hepatocyte surface. This abundance of receptors increases the liver's capacity to capture and remove circulating LDL-C and other atherogenic particles from the bloodstream, causing a sustained reduction in plasma LDL-C levels. This accelerated clearance is the primary physiological consequence of the drug’s mechanism.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Atorvastatine EG is administered through the oral route as a film-coated tablet, available in four strengths ranging from 10 mg to 80 mg. The official dosing schedule dictates that the medicine be taken once daily, and the daily dose may be ingested with or without food. This flexibility allows the drug to be taken at any time of the day. The use of Atorvastatine is always defined as an adjunct to a standard cholesterol-lowering diet.

For adults, treatment typically begins with a starting dose of 10 mg or 20 mg once daily. The standard dosage range extends up to a maximum daily dose of 80 mg. Adjusting the dosage, known as titration, must be assessed systematically at intervals of four weeks or more to allow the full therapeutic effect to be established before any change.

Specific procedural rules apply to certain populations and circumstances. No dose adjustment is required for older adults or for patients with renal impairment. For pediatric patients (aged 10 years and older), starting and maximum doses are specified according to the indication, with the range typically limited to 10 mg to 20 mg daily for certain hypercholesterolemia types. When the medicine is co-administered with certain strong CYP3A4 inhibitors, such as clarithromycin, the official label imposes a maximum daily dose limit for Atorvastatin. If a dose is missed, standard instructions advise the patient to skip the missed dose and resume the regular dosing schedule with the next planned administration.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Atorvastatine EG


Evidence for Lipid Management in Primary and Mixed Dyslipidemia

Research exploring the effects of Atorvastatin on blood fats primarily involved Randomized Controlled Trials (RCTs). These studies were designed to evaluate the compound compared to inactive substances (placebo) or other similar agents over short to intermediate follow-up durations. The main outcomes research examined were specific lipid biomarkers, such as measurements of Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and Triglycerides.

Studies consistently reported measurements showing a measured change in LDL-C and Total Cholesterol levels compared to baseline measurements. This evidence contributes to understanding patterns measured in the levels of fatty substances in the blood, an outcome related to systemic imbalance. However, data for certain rare forms of dyslipidemia remain insufficient for drawing broad conclusions about their unique patient patterns.


Evidence for Reducing Risk in Established Heart Disease

The research base for individuals with established heart disease involves large-scale, long-term RCTs. Research examined the incidence of Major Adverse Cardiovascular Events (MACE), a composite outcome that includes non-fatal heart attacks, strokes, and the need for revascularization procedures. These studies included adults who already had a history of heart attack or confirmed Coronary Heart Disease (CHD).

Research described that the observed patterns of MACE incidence differed between the groups receiving the compound and comparator groups over follow-up periods of several years. This research contributes to the broader evidence landscape by providing context on event incidence patterns in high-risk patients. The certainty remains low regarding research outcomes for the very oldest age groups (e.g., adults ge 76 years), as these subgroups were less represented in the primary trials.


Long-Term Research and Study Follow-up

Research involving major clinical events often requires long-term follow-up, typically tracking patients for three to five years or longer. Studies monitored event incidence and patterns of mortality over these defined, multi-year durations. These long-term studies help show what has been observed so far regarding the patterns measured over time.

Limited information exists for long-term outcomes and the durability of effects beyond the defined end points of the key clinical trials. Data are still emerging for long-term effects, particularly those lasting a decade or more, in large-scale dedicated RCTs.

Key Studies & References Atorvastatin (Oral Route) - NIH MedlinePlus Drug Information

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Atorvastatine EG (FAQ)


Q: Can Atorvastatine EG be taken with other cholesterol medications?

Official documentation notes that certain lipid-modifying agents, such as Fibric Acid Derivatives and Niacin at doses of 1 gram per day or more, are associated with an increased risk of muscle problems when used with Atorvastatine EG. The management of cholesterol-lowering therapies in combination with Atorvastatine EG requires professional management due to potential muscle-related risks.


Q: What foods should be avoided when taking Atorvastatine EG?

Official regulatory product information specifies that consumption of large quantities of grapefruit juice (exceeding 1.2 liters daily) is not recommended, as this can increase the plasma levels of the medicine. Apart from this specific caution, the drug is defined in regulatory guidelines as an adjunct to a standard cholesterol-lowering diet.


Q: Is Atorvastatine EG the same as Lipitor?

Atorvastatine EG is a brand name containing the active substance Atorvastatin. The medicine Lipitor is also a widely recognized brand name for the same active ingredient. Generic Atorvastatin products, including Atorvastatine EG, are approved by regulatory bodies based on bioequivalence to the original brand-name medicine.


Q: Is Atorvastatine EG safe for older adults?

Official documents state that no dose adjustment is routinely required for older adults. However, regulatory warnings note that patients aged 70 years and older have an officially noted higher risk of developing a muscle disorder, such as myopathy. Due to these factors, official documents note caution regarding use in this population.


Q: Does Atorvastatine EG interact with vitamins or supplements?

Official guidance documents list specific supplements that may interact with Atorvastatine EG. For example, the use of Niacin at doses of 1 gram per day or more is associated with an increased risk of muscle problems. Additionally, the herbal remedy St John's wort can reduce the concentration of the drug in the blood, potentially making it less effective.


Q: Does taking Atorvastatine EG require a special diet?

According to the official administration guidelines, the medicine is officially defined as an adjunct to a standard cholesterol-lowering diet. This means the drug is intended to be used along with general dietary measures aimed at lowering cholesterol, rather than requiring a highly restrictive or complex 'special diet.'


Q: Is Atorvastatine EG affected by alcohol consumption?

Official labeling notes caution for individuals with predisposing factors for muscle disorders, including a history of liver disease or substantial alcohol consumption. This information highlights that heavy alcohol use can contribute to risk factors associated with the medicine.


Q: Does Atorvastatine EG affect kidney function?

Official documents state that no dose adjustment is necessary for patients who have kidney impairment. However, kidney impairment is officially listed as a predisposing factor that may increase a person's risk of developing serious muscle disorders like myopathy or rhabdomyolysis.


Q: What are the general expectations for people who use Atorvastatine EG?

Based on research, the general expectations are related to the measured effects on blood lipids and cardiovascular risk. Studies indicate a sustained reduction in circulating LDL-C levels (often called 'bad' cholesterol) and measured differences in the incidence of serious heart-related events (MACE) over long-term follow-up.


Q: How quickly does Atorvastatine EG start working?

Official regulatory documentation indicates that the therapeutic response for lowering cholesterol is typically evident within 2 weeks of starting treatment. The maximum therapeutic response is usually achieved within 4 weeks.


Q: How long does it take to see results from Atorvastatine EG?

For the measured lipid-lowering effects, official regulatory text indicates that the maximum therapeutic response is generally achieved within 4 weeks of starting treatment. Long-term studies on cardiovascular events often track results over several years.


Q: Do I have to take Atorvastatine EG forever?

Statins, including Atorvastatine EG, are often described in clinical guidelines as being for life-long use in certain high-risk patient populations. Regulatory patient information notes that stopping the therapy may cause cholesterol levels to increase, which could raise the risk of heart attack or stroke.


Q: Is it normal to feel tired when starting Atorvastatine EG?

Some official side effect reporting indicates that feeling unusually tired or physically weak has been documented as a side effect sometimes reported with statin use. This is a general observation related to the class of medicine, and the frequency of this specific symptom is typically low.


Q: What are the signs of a serious reaction to Atorvastatine EG?

Regulatory patient information describes several signs of serious reactions. For serious muscle problems, signs may include unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever. Signs of potential liver damage may include dark-colored urine, yellowing of the skin or eyes, or upper right stomach pain.


Q: How is Atorvastatine EG different from other generic atorvastatin products?

Generic medications, including Atorvastatine EG, are approved by regulatory bodies based on their demonstration of bioequivalence to the original brand-name medicine. This means they contain the same active ingredient and are expected to work in the same way. Research comparing generic Atorvastatin products generally finds no significant differences in patient outcomes.


Q: Is it true that Atorvastatine EG is sometimes prescribed to non-diabetics?

Yes, the primary purpose of Atorvastatine EG is the management of high blood lipids, a condition known as dyslipidemia, which affects both diabetic and non-diabetic adults. The official indications allow for use in any adult with approved conditions, regardless of their diabetes status.


Q: Does Atorvastatine EG have any effect on blood pressure?

Research has investigated the effects of Atorvastatin on blood pressure beyond its primary function. Some studies have observed a reduction in blood pressure in certain patient groups, while other reports have indicated inconsistent or no effect on blood pressure overall.


Q: What kind of monitoring is typically required when taking Atorvastatine EG?

Regulatory-aligned guidelines typically describe that a baseline lipid profile (blood fat test) is necessary before starting therapy, and rechecking it periodically to confirm the medicine's effect. Liver function tests (LFTs) are also described as necessary at baseline and should be performed if a patient develops symptoms of liver disease.


Q: What should I do if I experience muscle weakness while on Atorvastatine EG?

Patient information from regulatory sources advises that unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever, is advised by patient information to be reported to a healthcare professional for evaluation. This is because these symptoms may be signs of a serious, though rare, muscle problem.


Q: Can Atorvastatine EG be split or crushed?

Atorvastatine EG is supplied as a film-coated tablet, which is designed for intact oral administration. While some clinical guidance notes that crushing or splitting may be feasible when necessary for specific patient needs, modification is outside of the standard regulatory scope.


Q: Is it common for people to switch from one statin to Atorvastatine EG?

Clinical experience, as noted in authoritative medical reviews, indicates that switching between different statin medications is a common management strategy. Healthcare professionals may utilize a change to address specific patient needs, such as managing symptoms like statin-associated muscle issues.


Q: Are there any known interactions between Atorvastatine EG and over-the-counter pain relievers?

There are typically no known direct interactions between Atorvastatin and common over-the-counter pain relievers like acetaminophen. However, because both Atorvastatine EG and acetaminophen are processed by the liver, general precaution is noted regarding the potential for liver injury from any source.


Q: What should be done before starting treatment with Atorvastatine EG?

Regulatory-aligned guidelines describe that obtaining a baseline lipid profile and liver function tests (LFTs) is necessary before starting statin therapy. This initial assessment helps to confirm eligibility and establish baseline values for the patient's cholesterol and liver health.


Q: Is it okay to stop taking Atorvastatine EG abruptly?

Patient information from regulatory sources notes that the medicine is not intended to be stopped abruptly without medical supervision. Cessation of therapy can cause cholesterol levels to increase, potentially raising the underlying risk of heart attack or stroke.


Q: Does Atorvastatine EG interact with herbal remedies?

Official guidance notes that the herbal supplement St John’s wort is known to interact, as it can reduce the amount of Atorvastatin in the blood and potentially make the drug less effective. The use of herbal remedies requires professional management due to potential interactions.


Q: Can I take Atorvastatine EG if I have diabetes?

Yes, statin treatment is often offered to people with diabetes to manage cardiovascular risk factors. However, official documents list hyperglycemia (elevated blood sugar) as a common adverse reaction with Atorvastatin. Due to this, blood sugar monitoring may be necessary during use.

Advertisements

How should Atorvastatine EG be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines strict conditions to maintain the stability and safety of Atorvastatin tablets.

Detail Regulatory Requirement
Storage Temperature Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F).
Environmental Protection Keep away from heat, moisture, and direct light; must not be frozen.
Packaging Keep the medicine in the original container, tightly closed.
Child Safety Keep out of the reach of children at all times.
Disposal Instructions Do not flush unused or expired medicine down a toilet or pour into a drain. Disposal must follow local pharmaceutical waste guidelines or the instructions of a healthcare professional.

Regulatory documents specify that any unused medicine must be discarded according to professional guidance, and outdated medicine should not be kept. Storage in damp areas like bathrooms is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atorvastatine EG found in:

A-Z Index: